Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.
Natasha Bahri, MD, MS
Advertisement
Articles by Natasha Bahri, MD, MS
Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.
Advertisement
Latest Updated Articles
Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?Published: November 12th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer
5
